Фармакоэкономический обзор зарубежных исследований применения ритуксимаба при лечении хронического лимфолейкоза
Р. И. Ягудина · Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология · 2009
This article contains data review of comparative assessment of cost-effectiveness rate of R-FC (rituximab, fludarabin, cyclophosphamide) versus FC-alone (fludarabin, cyclophosphamide) and R-FC (rituximab, fludarabin, cyclophosphamide) versus monotherapy with chlorambucil in treatment of Chronic Lymphocytic Leukemia (CLL). Results of the reviewed studies demonstrate beneficial rate of all pharmacoeconomic values for R-FC regimen for CLL treatment.
Cited by 0 works.